Cyclooxygenase-2 (COX-2), an inducible prostaglandin synthase, is normally expressed in parts of the kidney and brain. Aberrant COX-2 expression was first reported in colorectal carcinomas and adenomas, and has now been detected in various human cancers, including those of the breast. Strikingly, COX-2 overexpression in murine mammary gland is sufficient to cause tumour formation. To date, the role of COX-2 in tumorigenesis has been most intensively studied in the colon. Thus, the relationship between COX-2 and neoplasia can best be illustrated with reference to intestinal tumorigenesis. Here we consider the potential utility of selective COX-2 inhibitors for the prevention and treatment of breast cancer. Data for cancers of the colon and breast are compared where possible. In addition, the mechanisms by which COX-2 is upregulated in cancers and contributes to tumorigenesis are discussed. Importantly, several recent studies of mammary tumorigenesis in animal models have found selective COX-2 inhibitors to be effective in the prevention and treatment of breast cancer. Clinical trials will be needed to determine whether COX-2 inhibition represents a useful approach to preventing or treating human breast cancer.

This article has been cited by other articles:

				M. F Dillon, A. T Stafford, G. Kelly, A. M Redmond, M. McIlroy, T. B Crotty, E McDermott, A. D Hill, and L. S Young Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients Endocr. Relat. Cancer, September 1, 2008; 15(3): 745 - 753. [Abstract] [Full Text] [PDF]

				A. Mustafa and W. D. Kruger Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor {gamma} Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer Clin. Cancer Res., August 1, 2008; 14(15): 4935 - 4942. [Abstract] [Full Text] [PDF]

				E.-H. Kim, H.-K. Na, D.-H. Kim, S.-A. Park, H.-N. Kim, N.-Y. Song, and Y.-J. Surh 15-Deoxy-{Delta}12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS Carcinogenesis, April 1, 2008; 29(4): 688 - 695. [Abstract] [Full Text] [PDF]

				X. Zhao, M. Goswami, N. Pokhriyal, H. Ma, H. Du, J. Yao, T. A. Victor, K. Polyak, C. D. Sturgis, H. Band, et al. Cyclooxygenase-2 Expression during Immortalization and Breast Cancer Progression Cancer Res., January 15, 2008; 68(2): 467 - 475. [Abstract] [Full Text] [PDF]

				L. R. Howe Rexinoids and Breast Cancer Prevention Clin. Cancer Res., October 15, 2007; 13(20): 5983 - 5987. [Full Text] [PDF]

				K. Kiguchi, L. Ruffino, T. Kawamoto, E. Franco, S.-i. Kurakata, K. Fujiwara, M. Hanai, M. Rumi, and J. DiGiovanni Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice Mol. Cancer Ther., June 1, 2007; 6(6): 1709 - 1717. [Abstract] [Full Text] [PDF]

				L. S. Fournier, V. Novikov, V. Lucidi, Y. Fu, T. Miller, E. Floyd, D. M. Shames, and R. C. Brasch MR Monitoring of Cyclooxygenase-2 Inhibition of Angiogenesis in a Human Breast Cancer Model in Rats Radiology, April 1, 2007; 243(1): 105 - 111. [Abstract] [Full Text] [PDF]

				H.-T. Kim, G. Kong, D. DeNardo, Y. Li, I. Uray, S. Pal, S. Mohsin, S. G. Hilsenbeck, R. Bissonnette, W. W. Lamph, et al. Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays Cancer Res., December 15, 2006; 66(24): 12009 - 12018. [Abstract] [Full Text] [PDF]

				M. Brunelle, E. A. Sartin, L. G. Wolfe, J. Sirois, and M. Dore Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Vet. Pathol., September 1, 2006; 43(5): 656 - 666. [Abstract] [Full Text] [PDF]

				K J Schmitz, R Callies, J Wohlschlaeger, R Kimmig, F Otterbach, J Bohr, H-S Lee, A Takeda, K W Schmid, and H A Baba Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways J. Clin. Pathol., July 1, 2006; 59(7): 685 - 691. [Abstract] [Full Text] [PDF]

				M. Mezhybovska, K. Wikstrom, J. F. Ohd, and A. Sjolander The Inflammatory Mediator Leukotriene D4 Induces beta-Catenin Signaling and Its Association with Antiapoptotic Bcl-2 in Intestinal Epithelial Cells J. Biol. Chem., March 10, 2006; 281(10): 6776 - 6784. [Abstract] [Full Text] [PDF]

				L. R. Howe, S.-H. Chang, K. C. Tolle, R. Dillon, L. J.T. Young, R. D. Cardiff, R. A. Newman, P. Yang, H. T. Thaler, W. J. Muller, et al. HER2/neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduced in Cyclooxygenase-2 Knockout Mice Cancer Res., November 1, 2005; 65(21): 10113 - 10119. [Abstract] [Full Text] [PDF]

				V. Marwaha, Y.-H. Chen, E. Helms, S. Arad, H. Inoue, E. Bord, R. Kishore, R. D. Sarkissian, B. A. Gilchrest, and D. A. Goukassian T-oligo Treatment Decreases Constitutive and UVB-induced COX-2 Levels through p53- and NF{kappa}B-dependent Repression of the COX-2 Promoter J. Biol. Chem., September 16, 2005; 280(37): 32379 - 32388. [Abstract] [Full Text] [PDF]

				J. H. Kim, V. Bossuyt, T. Ponn, D. Lannin, and B. G. Haffty Cyclooxygenase-2 Expression in Postmastectomy Chest Wall Relapse Clin. Cancer Res., July 15, 2005; 11(14): 5199 - 5205. [Abstract] [Full Text] [PDF]

				G. Kong, H.-T. Kim, K. Wu, D. DeNardo, S. G. Hilsenbeck, X.-C. Xu, W. W. Lamph, R. Bissonnette, A. J. Dannenberg, and P. H. Brown The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention Cancer Res., April 15, 2005; 65(8): 3462 - 3469. [Abstract] [Full Text] [PDF]

				J.-S. Cadieux, P. Leclerc, M. St-Onge, A.-A. Dussault, C. Laflamme, S. Picard, C. Ledent, P. Borgeat, and M. Pouliot Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal J. Cell Sci., April 1, 2005; 118(7): 1437 - 1447. [Abstract] [Full Text] [PDF]

				M. Heinonen, P. Bono, K. Narko, S.-H. Chang, J. Lundin, H. Joensuu, H. Furneaux, T. Hla, C. Haglund, and A. Ristimaki Cytoplasmic HuR Expression Is a Prognostic Factor in Invasive Ductal Breast Carcinoma Cancer Res., March 15, 2005; 65(6): 2157 - 2161. [Abstract] [Full Text] [PDF]

				K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2 Am. J. Pathol., February 1, 2005; 166(2): 575 - 584. [Abstract] [Full Text] [PDF]

				D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]

				C. T. Dang, A. J. Dannenberg, K. Subbaramaiah, M. N. Dickler, M. M. Moasser, A. D. Seidman, G. M. D'Andrea, M. Theodoulou, K. S. Panageas, L. Norton, et al. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments Clin. Cancer Res., June 15, 2004; 10(12): 4062 - 4067. [Abstract] [Full Text] [PDF]

				M. B. Terry, M. D. Gammon, F. F. Zhang, H. Tawfik, S. L. Teitelbaum, J. A. Britton, K. Subbaramaiah, A. J. Dannenberg, and A. I. Neugut Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk JAMA, May 26, 2004; 291(20): 2433 - 2440. [Abstract] [Full Text] [PDF]

				K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin Carcinogenesis, May 1, 2004; 25(5): 713 - 722. [Abstract] [Full Text] [PDF]

				K.-S. Chun, H.-H. Cha, J.-W. Shin, H.-K. Na, K.-K. Park, W.-Y. Chung, and Y.-J. Surh Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-{kappa}B Carcinogenesis, March 1, 2004; 25(3): 445 - 454. [Abstract] [Full Text] [PDF]

				S. Han, H. Inoue, L. C. Flowers, and N. Sidell Control of COX-2 Gene Expression through Peroxisome Proliferator-Activated Receptor {gamma} in Human Cervical Cancer Cells Clin. Cancer Res., October 1, 2003; 9(12): 4627 - 4635. [Abstract] [Full Text] [PDF]

				L. Fajas, S. Miard, M. R. Briggs, and J. Auwerx Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase J. Lipid Res., September 1, 2003; 44(9): 1652 - 1659. [Abstract] [Full Text] [PDF]

				K.-S. Chun, Y.-S. Keum, S. S. Han, Y.-S. Song, S.-H. Kim, and Y.-J. Surh Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-{kappa}B activation Carcinogenesis, September 1, 2003; 24(9): 1515 - 1524. [Abstract] [Full Text] [PDF]

				H. Nishihara, S. Kizaka-Kondoh, P. A. Insel, and L. Eckmann Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2 PNAS, July 22, 2003; 100(15): 8921 - 8926. [Abstract] [Full Text] [PDF]

				M. Dore, I. Lanthier, and J. Sirois Cyclooxygenase-2 Expression in Canine Mammary Tumors Vet. Pathol., March 1, 2003; 40(2): 207 - 212. [Abstract] [Full Text] [PDF]

				N. Heuze-Vourc'h, L. Zhu, K. Krysan, R. K. Batra, S. Sharma, and S. M. Dubinett Abnormal Interleukin 10R{alpha} Expression Contributes to the Maintenance of Elevated Cyclooxygenase-2 in Non-Small Cell Lung Cancer Cells Cancer Res., February 15, 2003; 63(4): 766 - 770. [Abstract] [Full Text] [PDF]

				M. Pouliot, M.-E. Fiset, M. Masse, P. H. Naccache, and P. Borgeat Adenosine Up-Regulates Cyclooxygenase-2 in Human Granulocytes: Impact on the Balance of Eicosanoid Generation J. Immunol., November 1, 2002; 169(9): 5279 - 5286. [Abstract] [Full Text] [PDF]

				O. C. Trifan, W. F. Durham, V. S. Salazar, J. Horton, B. D. Levine, B. S. Zweifel, T. W. Davis, and J. L. Masferrer Cyclooxygenase-2 Inhibition with Celecoxib Enhances Antitumor Efficacy and Reduces Diarrhea Side Effect of CPT-11 Cancer Res., October 15, 2002; 62(20): 5778 - 5784. [Abstract] [Full Text] [PDF]

				L. R. Howe, K. Subbaramaiah, J. Patel, J. L. Masferrer, A. Deora, C. Hudis, H. T. Thaler, W. J. Muller, B. Du, A. M. C. Brown, et al. Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, Protects against Human Epidermal Growth Factor Receptor 2 (HER-2)/neu-induced Breast Cancer Cancer Res., October 1, 2002; 62(19): 5405 - 5407. [Abstract] [Full Text] [PDF]

				C. Gerhauser, A. Alt, E. Heiss, A. Gamal-Eldeen, K. Klimo, J. Knauft, I. Neumann, H.-R. Scherf, N. Frank, H. Bartsch, et al. Cancer Chemopreventive Activity of Xanthohumol, a Natural Product Derived from Hop Mol. Cancer Ther., September 1, 2002; 1(11): 959 - 969. [Abstract] [Full Text] [PDF]

				A. Ristimaki, A. Sivula, J. Lundin, M. Lundin, T. Salminen, C. Haglund, H. Joensuu, and J. Isola Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer Cancer Res., February 1, 2002; 62(3): 632 - 635. [Abstract] [Full Text] [PDF]